Recruiting
Secondary immunodeficiency
RecruitingStudy of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy
Registered drugNo placebo
Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy
Registered drugNo placebo
- Disease:Secondary immunodeficiency
- Substances:TeclistamabHuman Normal Immunoglobulin
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Teclistamab
- Sponsor:Takeda Development Center Americas Inc.




